Transgene says TG4010 meets primary endpoint in Phase IIb lung cancer trial
French biotech company Transgene said the primary endpoint has been achieved in a Phase IIb trial evaluating its therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to first line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
This entry was posted on Monday, June 2nd, 2008 at 12:26 pm and is filed under Research, Non-Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.